QuorumCivic. Hidden in plain sight Get the app
Bill intelligence
Full Simple

Bill speeds up approval of generic complex drugs.

H.R. 9661 — Expedited Access to Biosimilars Act · Filed by Nicholas Langworthy (R-NY) · 2 cosponsors · Introduced Jul 14, 2026 · Referred to committee

65%
How clear the bill is
Typical bill: 85%
25/100
Chance of hidden extras
Typical bill: 15/100
Regulatory Deregulation / Biosimilar…

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

The bill changes how the FDA approves biosimilars. Biosimilars are generic versions of complex drugs. Right now, companies must do expensive studies. This bill says companies only need to show molecular similarity. The FDA can still require more studies. It must write down why and notify the company.

Who it affects

Patients could get cheaper complex drugs faster. Drug companies that make biosimilars could launch sooner. Companies that make original drugs face faster competition.

One thing to notice

The bill shifts the burden to the FDA. Instead of companies proving their drug works, the FDA must prove it needs more proof.

From the analysis of the bill text, linked under Primary records below.

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

  • Jul 14, 2026 — Introduced · Congress.gov: “Introduced in House”
  • Jul 14, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

8 groups reported lobbying about this bill. They filed 11 reports from Jun 2026 to Sep 2026.

Those reports show $18,420,000 in lobbying spending. Each report lists about 26 bills. So that money was not all for this bill.

More groups named this bill than 85% of bills with any report.

Nicholas Langworthy, who sponsored the bill, received $1,132,611 from PACs for the 2026 election.

  • Pharmaceutical Research and Manufacturers of America — $14,400,000 in 2 reports
  • Gsk (fka Glaxosmithkline Inc.) — $1,530,000 in 1 report
  • Association for Accessible Medicines — $770,000 in 1 report
  • Blood Cancer United (fka the Leukemia & Lymphoma Society) — $710,000 in 2 reports
  • American Society of Health-system Pharmacists — $510,000 in 2 reports

Lobbying is legal. These reports show who lobbied about this bill, not what changed.

Words to know

  • biosimilar — A generic version of a complex drug made from living cells.
  • FDA — The government agency that approves drugs before they can be sold.
  • lobbying — Trying to influence lawmakers about a bill. Companies and groups pay people to do this.
  • PACs — Groups that collect money and give it to candidates for office.
  • sponsored — To sponsor a bill is to introduce it in Congress and put your name on it.

How this was measured

Analysis — Quorum's AI read the bill text published by Congress.gov (2,300 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.

Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.

Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.

As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.

“Bill speeds up approval of generic complex drugs.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr9661/simple Report an error

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record

The week in bills

One email, Sunday: what Congress passed, what it changed, and who paid.

One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.